Generic Name and Formulations:
Silver sulfadiazine 1%; cream.
Indications for SILVADENE:
Prophylaxis and treatment of sepsis in 2nd and 3rd degree burns.
Apply 1–2 times daily aseptically to approximately 1/16 inch depth to cleansed and debrided burns. Reapply promptly if removed. Continue until wound closed.
Premature infants. Within first 2 months of birth. Late pregnancy.
G6PD deficiency. Impaired renal or hepatic function. Monitor serum sulfa levels and renal function in extensive burns. Avoid eyes. Pregnancy (Cat.B). Nursing mothers: not recommended.
Leukopenia increased with concomitant cimetidine. May inactivate debriding enzymes.
Transient leukopenia, skin necrosis, erythema multiforme, skin discoloration, burning sensation, rash, pruritus, interstitial nephritis, reduction in bacterial growth; systemic sulfonamide reactions, fungal overgrowth.
Crm—20g, 50g, 85g, 400g, 1000g
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|